ArticleFrontiers in surgery2025
Defining the optimal Ki67 cutoff values for survival prediction in neoadjuvant chemotherapy-treated patients with breast cancer.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The rising incidence of breast cancer underscores the need for precise prognostic assessment following neoadjuvant chemotherapy (NAC). Ki67 is widely utilized for prognostic evaluation. However, its clinical applicability remains debated, particularly regarding the optimal cutoff threshold. This study aims to establish the optimal Ki67 cutoff value and evaluate its prognostic significance in predicting survival outcomes in patients with breast cancer undergoing NAC. Methods: A retrospective analysis was performed on 255 patients with breast cancer who received NAC between 2011 and 2024. The optimal Ki67 cutoff value was determined using maximally selected rank statistics. Kaplan-Meier survival analysis was used to evaluate the impact of Ki67 on disease-free survival (DFS) and overall survival (OS). Prognostic variables were selected via Cox regression analysis combined with LASSO dimensionality reduction. Based on these findings, nomogram models incorporating Ki67 and other clinical parameters were constructed to predict 1-year, 3-year, and 5-year DFS and OS, and the models were subsequently evaluated. Results: As a continuous variable, Ki67 presented an increasing and non-linear association with the risk of DFS. Using 20% as the threshold, survival analysis indicated that patients with a high Ki67 proliferation index (Ki67 > 20%) had significantly shortened DFS and OS compared to those with low Ki67 proliferation index. Cox regression analysis also confirmed that Ki67 was a common independent prognostic predictor for both DFS and OS. The nomogram model integrating Ki67, T stage, N stage, and other clinical parameters exhibited strong predictive performance, with the area under the curve (AUC) exceeding 0.900 at all-time points. Calibration plot further validated the model's accuracy, with a C-index of 0.894 for DFS and 0.788 for OS. Conclusions: A Ki67 cutoff of 20% serves as a reliable predictor of DFS and OS in patients with breast cancer receiving NAC. The developed nomogram models, incorporating Ki67 and other clinical parameters, provide an accurate and clinically valuable tool for individualized prognostic assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.